Regulatory Compliance Update
Alembic Pharmaceuticals Receives USFDA EIR for Injectable Facility at Karakhadi
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals Limited has received an Establishment Inspection Report (EIR) from the USFDA for its Injectable Facility (F-III) located at Karakhadi. The inspection was conducted between February 9 and February 18, 2026.
PRICE-SENSITIVE TRIGGER
Event: Receipt of USFDA Establishment Inspection Report (EIR)
Type: Regulatory Compliance Update
Impact: Positive
Immediate Effect: Receipt of the EIR indicates successful closure of the USFDA inspection process for the Karakhadi injectable facility, supporting regulatory credibility and export operations.
Key Metrics:
- Inspection Period: February 9, 2026 to February 18, 2026
- Facility: Injectable Facility (F-III), Karakhadi
- Regulatory Authority: USFDA
- EIR Receipt Date: May 13, 2026
Highlight:
- Label: Regulatory Milestone
- Value: USFDA EIR received for Karakhadi Injectable Facility
What Happened ?
Alembic Pharmaceuticals Limited informed stock exchanges that it has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Injectable Facility (F-III) located at Karakhadi.
The USFDA inspection for the facility was conducted from February 9, 2026 to February 18, 2026. Receipt of the EIR generally signifies closure of the inspection process.
The development strengthens the company’s compliance standing for regulated markets, particularly the United States.
key highlights
Inspection Outcome & regulatory Significance:
- Alembic received EIR from the USFDA for its Injectable Facility (F-III).
- The facility is located at Karakhadi.
- USFDA inspection was conducted between February 9 and February 18, 2026.
- The EIR was received on May 13, 2026.
- Receipt of EIR indicates successful completion of the inspection cycle.
- The facility supports Alembic’s injectable manufacturing operations for regulated markets.
- The update enhances the company’s regulatory compliance profile.
Note:
- USFDA EIR receipt is considered an important operational and regulatory milestone for pharmaceutical exporters serving highly regulated markets.
Risk Analysis
Key Risks
- Pharmaceutical manufacturing facilities remain subject to future inspections.
- Any future observations or compliance lapses could impact operations.
- Regulatory standards in injectable manufacturing are highly stringent.
- Export revenues remain dependent on continued regulatory approvals and market demand.
Worst Case Scenario
- Any adverse future regulatory observations could affect manufacturing continuity, product approvals, or exports to regulated markets.
Risk Level: Low
Company Commentary
- Alembic Pharmaceuticals received an Establishment Inspection Report from the USFDA.
- The EIR pertains to the Injectable Facility (F-III) at Karakhadi.
- The USFDA inspection was conducted in February 2026.
- The company requested exchanges to take the information on record.
Official Exchange Filing: Alembic Pharmaceuticals Limited